SCHEDULE: RTW Investments Discloses 6.1% Stake in Apellis Pharma

RTW Investments, LP and Managing Partner Roderick Wong, M.D. have disclosed a 6.1% beneficial ownership stake in Apellis Pharmaceuticals, Inc.

Summary

• RTW Investments, LP and Roderick Wong, M.D. collectively reported beneficial ownership of 7,666,764 shares of Apellis Pharmaceuticals, Inc. Common Stock.
• This ownership represents 6.1% of the outstanding shares of Apellis Pharmaceuticals, Inc.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The percentage of class is calculated based on 126,525,218 shares outstanding as of October 23, 2025, as reported in Apellis's Form 10-Q.
• Both RTW Investments, LP and Roderick Wong, M.D. share voting and dispositive power over all 7,666,764 shares.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as a significant stake from a reputable life sciences investor like RTW Investments suggests a strong belief in Apellis Pharmaceuticals' long-term value proposition.

Positives

• A significant 6.1% stake by a specialized investment firm like RTW Investments, LP, which focuses on life sciences, can signal confidence in Apellis Pharmaceuticals' future prospects and pipeline.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment thesis rather than an activist play.

Negatives

• The filing itself does not contain any negative information regarding Apellis Pharmaceuticals, Inc. or the reporting persons.

Risks

• The filing does not detail specific risks related to Apellis Pharmaceuticals, Inc. beyond the inherent risks of investing in common stock.

Future Outlook

The filing does not provide a future outlook for Apellis Pharmaceuticals, Inc. It primarily discloses the current ownership stake of RTW Investments, LP and Roderick Wong, M.D. The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Management Comments

• "The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that a significant stake by a specialized life sciences investment firm like RTW Investments, LP, which has a strong track record in the biotechnology and pharmaceutical sectors, often signals a vote of confidence in the underlying company's technology, pipeline, or market potential. This can be particularly impactful in the biotech industry where R&D success and regulatory approvals are key value drivers.

Comparison to Industry Standards

• This Schedule 13G filing primarily concerns an ownership disclosure and does not contain financial or operational data that would allow for a direct comparison to industry-standard performance benchmarks or specific comparable companies' project results.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investment may instill greater confidence in the company's prospects, potentially leading to increased investor interest and positive share price movement.
• Company Management: A large institutional holder like RTW Investments may engage with management, providing strategic input or oversight, though the filing states the stake is not for influencing control.

Next Steps

• Subsequent amendments to this Schedule 13G statement will be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

Key Dates

Recommendation

A significant 6.1% stake by RTW Investments, LP, a highly respected investment firm specializing in life sciences, signals strong conviction in Apellis Pharmaceuticals, Inc. For a seasoned investor, this institutional backing, particularly from a firm known for its deep industry expertise and due diligence, often serves as a compelling 'strong buy' signal, suggesting potential for future growth and value appreciation.

Keywords

Apellis Pharmaceuticals, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Institutional Investment, Biotechnology, Pharmaceuticals, Common Stock, Investment Adviser